Search results

Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.

Result type

Technology appraisal guidance

Published

21 February 2018

Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee in adults.

Result type

Technology appraisal guidance

Published

7 March 2018

Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

Result type

Technology appraisal guidance

Published

21 March 2018

Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.

Result type

Technology appraisal guidance

Published

15 November 2017

Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

22 November 2017

Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.

Result type

Technology appraisal guidance

Published

1 November 2017

Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.

Result type

Technology appraisal guidance

Last updated

25 September 2017

Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.

Result type

Technology appraisal guidance

Last updated

12 September 2017

Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

Result type

Technology appraisal guidance

Published

11 October 2017

Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

Result type

Technology appraisal guidance

Published

11 October 2017

Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.

Result type

Technology appraisal guidance

Published

1 November 2017

Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.

Result type

Technology appraisal guidance

Published

4 October 2017

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.

Result type

Technology appraisal guidance

Published

4 October 2017

Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.

Result type

Technology appraisal guidance

Published

4 October 2017

Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis in adults.

Result type

Technology appraisal guidance

Published

11 October 2017